Backed by OrbiMed and Longitude, Phase 1 biotech 89bio (ETNB) is expected to raise $70 million tonight in the fifth NASH-focused biotech IPO of 2019; insiders have indicated on $40 million (57% of the deal). Another NASH...read more
Ridesharing giant Uber (UBER) made its debut this week, raising $8.1 billion dollars at a market cap of $82 billion, making it the largest US IPO since Alibaba went public in 2014. Uber priced its IPO at $45, 4% below the midpoint of the $44...read more
Axcella Health, which is developing amino acid-based therapies to treat liver and other diseases, raised $71 million by offering 3.6 million shares at $20, the low end of the range of $20 to $22. Axcella Health plans to list on the Nasdaq under the symbol AXLA...read more
Axcella, which is developing amino acid-based therapies to treat liver and other diseases, added insider buying to its upcoming $75 million IPO. The company still plans to sell 3.6 million shares at a price of $20-$22, but now states that certain of its...read more
NASHville: 89bio is the latest biotech IPO targeting liver disease NASH
Backed by OrbiMed and Longitude, Phase 1 biotech 89bio (ETNB) is expected to raise $70 million tonight in the fifth NASH-focused biotech IPO of 2019; insiders have indicated on $40 million (57% of the deal). Another NASH...read more
US IPO Weekly Recap: Uber falls 8% in a disappointing debut
Ridesharing giant Uber (UBER) made its debut this week, raising $8.1 billion dollars at a market cap of $82 billion, making it the largest US IPO since Alibaba went public in 2014. Uber priced its IPO at $45, 4% below the midpoint of the $44...read more
Axcella Health prices IPO at $20, the low end of the range
Axcella Health, which is developing amino acid-based therapies to treat liver and other diseases, raised $71 million by offering 3.6 million shares at $20, the low end of the range of $20 to $22. Axcella Health plans to list on the Nasdaq under the symbol AXLA...read more
Axcella adds insider buying ahead of $75 million IPO
Axcella, which is developing amino acid-based therapies to treat liver and other diseases, added insider buying to its upcoming $75 million IPO. The company still plans to sell 3.6 million shares at a price of $20-$22, but now states that certain of its...read more